Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...
Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf ...
With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...
Bio-Rad develops products and solutions for the life science research and clinical diagnostic markets and has niche market leadership in diagnostic quality controls, antigens, and digital polymerase ...
The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading "Use of Non-GAAP Reporting." A reconciliation ...
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results